news
NOVOS Core trial shows arterial stiffness drops over six months
A six-month randomized trial from the University of Surrey found NOVOS Core improved endothelial function and dropped systolic blood pressure in healthy adults. Arterial stiffness eased measurably across the cohort, though blood lipid panels stayed unchanged. It is a rare clinical trial test for a consumer longevity powder instead of a prescription drug.
A six-month randomized trial from the University of Surrey found NOVOS Core improved endothelial function and dropped systolic blood pressure in healthy adults. Arterial stiffness eased measurably across the cohort, though blood lipid panels stayed unchanged. It is a rare clinical trial test for a consumer longevity powder instead of a prescription drug.
The architecture take
I used to lump multi-ingredient longevity powders into the expensive-urine pile, so I paid attention when this Surrey trial landed. Testing an over-the-counter sachet in a six-month human RCT is gutsy when most supplement brands prefer mouse data (which cost a fraction of the budget). I expected zero vascular movement. Instead, the win showed up in nitric oxide production and endothelial flex rather than cholesterol clearance. When arterial walls stay pliable, systolic pressure drops and your heart works against less resistance. Your nervous system feels that directly because peripheral vascular resistance sets your sympathetic baseline load. The catch is that lipids didn't budge at all. If someone buys this expecting their ApoB to drop, they'll be disappointed. I want to see if independent replication holds up once the novelty wears off. For now, it forces competitors still hiding behind petri-dish data to step into a clinic.